Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

BACKGROUND A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection. METHODS A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2 : 1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months. RESULTS A total of 5403 volunteers (5095 men and 308 women) were evaluated. The vaccine did not prevent HIV-1 acquisition: infection rates were 6.7% in 3598 vaccinees and 7.0% in 1805 placebo recipients; vaccine efficacy (VE) was estimated as 6% (95% confidence interval, -17% to 24%). There were no significant differences in viral loads, rates of antiretroviral-therapy initiation, or the genetic characteristics of the infecting HIV-1 strains between treatment arms. Exploratory subgroup analyses showed nonsignificant trends toward efficacy in preventing infection in the highest risk (VE, 43%; n=247) and nonwhite (VE, 47%; n=914) volunteers (P=.10, adjusted for multiple subgroup comparisons). CONCLUSIONS There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches.

[1]  T. Wrin,et al.  Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. , 1996, The Journal of infectious diseases.

[2]  J. Rosenblatt,et al.  Prevalence studies of GB Virus‐C infection using reverse transcriptase‐polymerase chain reaction , 1996, Journal of medical virology.

[3]  M. Nolan,et al.  HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. , 2004, The Journal of infectious diseases.

[4]  A. McMichael,et al.  HIV vaccines 1983–2003 , 2003, Nature Medicine.

[5]  A. Wald,et al.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. , 2002, The Journal of infectious diseases.

[6]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[7]  D. Morens,et al.  Antibody-dependent enhancement of infection and the pathogenesis of viral disease. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Kahn,et al.  Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[9]  J. Esparza,et al.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.

[10]  D. Francis,et al.  Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials , 2003, AIDS.

[11]  Luc Montagnier,et al.  HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene , 1998, The Lancet.

[12]  R. Pomerantz,et al.  HIV and GB virus C--can two viruses be better than one? , 2004, The New England journal of medicine.

[13]  K. Mills,et al.  The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. , 1999, Vaccine.

[14]  J. Stapleton,et al.  Interactions between GB virus type C and HIV , 2002, Current infectious disease reports.

[15]  G. Nabel.  Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.

[16]  R. Seder,et al.  CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates1 , 2002, The Journal of Immunology.

[17]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[18]  J. Margolick,et al.  Persistent GB virus C infection and survival in HIV-infected men. , 2004, The New England journal of medicine.

[19]  R. Zinkernagel.  Are HIV-specific CTL responses salutary or pathogenic? , 1995, Current opinion in immunology.

[20]  Donald S. Burke,et al.  Human HIV Vaccine Trials: Does Antibody-Dependent Enhancement Pose a Genuine Risk? , 2015, Perspectives in biology and medicine.

[21]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[22]  J. Skurnick,et al.  Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Malchiodi,et al.  Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. , 2003, Vaccine.

[24]  E. Furth,et al.  Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response , 2003, Hepatology.

[25]  P. Spearman.  HIV vaccine development: lessons from the past and promise for the future. , 2003, Current HIV research.

[26]  N. Nagelkerke,et al.  Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya , 1996, The Lancet.

[27]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[28]  T. Wrin,et al.  Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. , 1999, Virology.

[29]  R. Belshe,et al.  Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. , 1994, JAMA.

[30]  E. Erbelding.  Glycoprotein D-adjuvant vaccine to prevent genital herpes. , 2003, Current infectious disease reports.

[31]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[32]  P. Berman,et al.  Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. , 2003, The Journal of infectious diseases.

[33]  R. Belshe,et al.  Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. , 1998, AIDS research and human retroviruses.

[34]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[35]  K. Steimer,et al.  Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2 , 1995, AIDS.

[36]  H. Sheppard,et al.  Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1 , 2004, Journal of acquired immune deficiency syndromes.

[37]  N. Nathanson,et al.  Biological considerations in the development of a human immunodeficiency virus vaccine. , 2000, The Journal of infectious diseases.

[38]  J. Bradac,et al.  The HIV vaccine pipeline, from preclinical to phase III , 2001, AIDS.

[39]  Barney S. Graham,et al.  Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 , 1994 .

[40]  B. Bloom.  The Highest Attainable Standard: Ethical Issues in AIDS Vaccines , 1998, Science.

[41]  S. Wünschmann,et al.  Effect of coinfection with GB virus C on survival among patients with HIV infection. , 2001, The New England journal of medicine.

[42]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[43]  J. Kostman,et al.  Recruitment and Baseline Epidemiologic Profile of Participants in the First Phase 3 HIV Vaccine Efficacy Trial , 2004, Journal of acquired immune deficiency syndromes.

[44]  Mark J. van der Laan,et al.  Choice of a null distribution in resampling-based multiple testing , 2004 .

[45]  p-value adjustments for subgroup analyses. , 1997, Journal of biopharmaceutical statistics.